Poland· PL-100432771
Mayzent
A siponimod product containing siponimodum, registered in Poland by Novartis Europharm Limited. The same ATC class is registered in 12 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Siponimod is registered in 12 of 19 countries.
Countries holding a registration under ATC L04AE03 (siponimod), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Siponimod · ATC L04AE03
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Italyprice
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of siponimod costs, country by country.
Normalised to the WHO defined daily dose (2 mg), so markets compare like for like.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Siponimod · price per daily dose (2 mg)
USD · FX 28 Sept 2026
- IT Italy$120.54
- CH Switzerland$118.82
The record
At a glance
URPL (Poland)- Active substance
- Siponimodum
- Manufacturer
- Novartis Europharm Limited
- Country
- Poland (PL)
- ATC code
- L04AE03
- ATC class
- Siponimod
- Defined daily dose
- 2 mg, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin07613421024581
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
667 interactions on record for siponimod.
Graded by severity as the source publishes them — 597 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Siponimod · interactions on record
667 records
- 597 severe
- 66 moderate
- 4 minor
Most severe, free to view
- CimetidineA02BA01severe
- RanitidineA02BA02severe
- FamotidineA02BA03severe
- NizatidineA02BA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Siponimod in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesMAYZENTNovartis Pharmaceuticals Corporation
- SpainMAYZENT 2 MG COMPRIMIDOS RECUBIERTOS CON PELICULANovartis Europharm Limited
- FinlandMayzentNovartis Europharm Limited
- SwitzerlandMayzent 2.00 mg, FilmtablettenNovartis Pharma Schweiz AG
- NetherlandsMayzent 2 mg, filmomhulde tablettenNovartis Europharm Limited
- SwedenMayzent 2 mg Filmdragerad tablettNovartis Europharm Limited
- IcelandMayzentNovartis Europharm Limited*
- United KingdomMayzent 0.25mg tabletsNovartis Pharmaceuticals UK Ltd
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Mayzent
- Liechtenstein · Mayzent
- Norway · Mayzent
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8ab26de6-7b2c-4b60-99b4-7f0ee5ab6112 GET /v1/drugs/8ab26de6-7b2c-4b60-99b4-7f0ee5ab6112?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "2 mg",
"packaging": "07613421024581 ¦ Rpz ¦ EU/1/19/1414/003 ¦ 135700\n28 tabl.\nRpz ¦ EU/1/19/1414/006 ¦ 148778\n98 tabl.\nRpz ¦ EU/1/19/1414/005 ¦ 148779\n14 tabl.",
"substance": "Siponimod 2 mg",
"common_name": "Siponimodum",
"pl_product_id": "100432771",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about siponimod.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.